Oncotelic Therapeutics Innovates Cancer Treatments Amid Competition from Iovance Biotherapeutics.

### Oncotelic Therapeutics: Pioneering Advances in Cancer Treatment

Oncotelic Therapeutics Inc., led by CEO Dr. Vuong Trieu, is making significant strides in the field of RNA-based medicines and immunotherapies aimed at addressing the pressing unmet medical needs of patients suffering from aggressive cancers such as glioblastoma and pancreatic cancer. These cancers present daunting challenges, with glioblastoma patients typically experiencing a median survival of only 15 months and a disheartening five-year survival rate of less than 5%. Similarly, pancreatic cancer is notorious for its grim prognosis, with only a 13% five-year survival rate. Recognizing these dire statistics, Oncotelic is committed to revolutionizing treatment options through innovative research and development, positioning itself as a leader in the oncology space.

Central to Oncotelic's strategy is its flagship program, OT-101, which aims to introduce novel treatment modalities for various cancers and rare diseases that currently lack effective therapies. The company employs a multidisciplinary approach, integrating advanced technologies such as artificial intelligence and nanomedicine into its research pipeline. This innovative methodology not only enhances the therapeutic potential of its drug candidates but also streamlines the development process, aiming to bring critical treatments to market more efficiently. Oncotelic's robust intellectual property portfolio, boasting approximately 500 patent applications and 75 granted patents, further solidifies its position as a formidable player in the biopharmaceutical landscape.

Beyond oncology, Oncotelic also addresses the substantial burden of rare diseases that afflict around 25-30 million Americans, many of whom are children. The lack of FDA-approved therapies for numerous rare conditions highlights the urgent need for new treatment options. Oncotelic's commitment to developing therapies for these populations underscores its dedication to alleviating human suffering and addressing significant public health challenges. As the company continues to expand its pioneering pipeline, it aims to align its innovative efforts with the growing demand for effective treatments, fostering long-term growth and making a meaningful impact in the healthcare sector.

In a competitive landscape that includes notable firms like Iovance Biotherapeutics, Merck, AstraZeneca, and Bristol-Myers Squibb, Oncotelic distinguishes itself through its focused approach to overcoming the limitations associated with traditional cancer therapies. The company's dedication to harnessing cutting-edge science for patient benefit positions it well for future advancements in both oncology and rare disease treatment paradigms.

As Oncotelic Therapeutics advances its research initiatives, it remains committed to transforming the treatment landscape for some of the most challenging medical conditions, thereby striving to fulfill the significant demand for innovative therapeutic solutions.